Monoclonal antibodies (MAb) in clinical oncology.
The clinical role of MAbs in the serum and immunohistochemical diagnostics is already established. Their potential usefulness for immunoscintigraphy is in the progress of evaluation and will probably be introduced in nuclear medical routine very soon. First clinical trials with special untagged or radiolabelled MAbs indicate their potency for the therapy of certain tumors. Clinical investigations with drug MAb conjugates have been started and will hopefully reveal significant therapeutic effects.